The use of anti-obesity therapy as indicated in IBD patients remains limited; although, reassuringly, GLP-1 based therapies appear to be safe and beneficial in obese patients with IBD and this should be encouraged in clinical practice. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.